Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SGM-101 fluorescence-guided surgery in locally advanced or recurrent rectal cancer
2019-001748-23Phase 3Active
- Sponsor
- Leiden University Medical Center
- Start
- Aug 2019
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label trial of sgm-101 in rectal cancer (2 arms), sponsored by Leiden University Medical Center. Primary endpoint: Concordance between intraoperative fluorescence assessment of resected lesions and histopathology. Started Aug 2019; status: active.
02
Drugs
sgm-101
03
Conditions
rectal cancer
Beyond the preview
Go deeper on 2019-001748-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001748-23.